The first step in the joint reimbursement process for Libmeldy® (atidarsagene autotemcel), a gene therapy product for the treatment of children with metachromatic leukodystrophy, was successfully…
The Beneluxa Initiative aims to ensure sustainable access
to innovative medicine at affordable cost for our patients.
Ireland, Belgium and the Netherlands complete joint HTA report on gene therapy Libmeldy
Joint statement at EPSCO Council June 2022: Market entry in Europe for drugs - evidence gaps and potential solutions
At the request of the members of the Beneluxa initiative (Belgium, the Netherlands, Luxembourg, Austria and Ireland) the market entry in Europe for medicines which lack conclusive evidence in…
Pharmaceutical Developments on Haemophilia
This report, written by the Taskforce Horizon Scanning of the Beneluxa Initiative, describes the current situation of Haemophilia and provides an overview of new pharmaceutical developments regarding…